Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DNUS02
|
|||
Drug Name |
IM1240
|
|||
Drug Type |
Antibody
|
|||
Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Preclinical | [1] | |
Company |
Purple
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | NKG2-A/B-activating NK receptor (NKG2A) | Target Info | . | [1] |
Oncotrophoblast glycoprotein 5T4 (TPBG) | Target Info | . | [1] | |
T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [1] | |
KEGG Pathway | Antigen processing and presentation | |||
Natural killer cell mediated cytotoxicity | ||||
Graft-versus-host disease | ||||
NetPath Pathway | TCR Signaling Pathway | |||
IL2 Signaling Pathway | ||||
Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
WikiPathways | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Purple |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.